ArticleJournal of inherited metabolic disease2007
Advanced glycation end products and the absence of premature atherosclerosis in glycogen storage disease Ia.
Article in Journal of inherited metabolic disease, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Are Advanced Glycation End Products in Skin Associated with Vascular Dysfunction Markers? A Meta-Analysis.International journal of environmental research and public health · 2020Pooled it
- Accelerated Biological Aging in Exfoliation Glaucoma Assessed by Fundus-Derived Predicted Age and Advanced Glycation End Products.International journal of molecular sciences · 2025Article
- Associations of Skin Autofluorescence with Diabetic Kidney Disease in Type 2 Diabetes.Biomedicines · 2025Article
- Reference Values of Skin Autofluorescence by Age Groups in Healthy Spanish Adults: Results from the EVasCu Study, a Systematic Review, and a Meta-Analysis.Journal of clinical medicine · 2025Review
- Prediction of mortality among patients with chronic kidney disease: A systematic review.World journal of nephrology · 2021Article
- Brain glycogen serves as a critical glucosamine cache required for protein glycosylation.Cell metabolism · 2021Article
- Advanced Glycation End Product Accumulation in Subjects with Open-Angle Glaucoma with and without Exfoliation.Antioxidants (Basel, Switzerland) · 2020Article
- The association between skin auto-fluorescence of palmoplantar sites and microvascular complications in Asian patients with type 2 diabetes mellitus.Scientific reports · 2018Article
- Role of advanced glycation end products in mobility and considerations in possible dietary and nutritional intervention strategies.Nutrition & metabolism · 2018Review
- Skin fluorescence as a clinical tool for non-invasive assessment of advanced glycation and long-term complications of diabetes.Glycoconjugate journal · 2016Review
- Article
- A new gender-specific model for skin autofluorescence risk stratification.Scientific reports · 2015Article
- Skin autofluorescence, a non-invasive marker for AGE accumulation, is associated with the degree of atherosclerosis.PloS one · 2013Article
- Dietary dilemmas in the management of glycogen storage disease type I.Journal of inherited metabolic disease · 2011Review
- Total oxidant-scavenging capacities of plasma from glycogen storage disease type Ia patients as measured by cyclic voltammetry, FRAP and luminescence techniques.Journal of inherited metabolic disease · 2009Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDespite their unfavourable cardiovascular risk profile, patients with glycogen storage disease type Ia (GSD Ia) do not develop premature atherosclerosis. We hypothesized that this paradox might be related to a decreased formation of advanced glycation end products (AGEs) resulting from lifetime low plasma glucose levels and decreased oxidative stress.
methodsIn 8 GSD Ia patients (age 20-34 years) and 30 matched controls we measured carotid intima-media thickness (IMT), skin autofluorescence (AF; a non-invasive index for AGEs), and specific AGEs (pentosidine, N-(carboxymethyl)lysine (CML), N-(carboxyethyl)lysine (CEL)) and collagen linked fluorescence (CLF, measured at excitation/emission wavelength combinations of 328/378 and 370/440 nm) in skin samples.
resultsCarotid IMT was significantly lower in GSD Ia patients. Skin AF did not differ between patients and controls. The skin samples showed higher CEL levels in the patient group (p = 0.008), but similar levels of pentosidine, CML, and CLF. In the total group, skin AF correlated with CML (r = 0.39, p = 0.031), CLF 328/378 nm (r = 0.53; p = 0.002) and CLF 370/440 nm (r = 0.60; p = 0.001). In the control group, AF also correlated with the maximum carotid IMT (r = 0.6; p = 0.004).
conclusionAlthough our data confirm that GSD Ia patients present with a reduced burden of atherosclerosis, this phenomenon cannot be explained by differences in AGE accumulation as measured in the skin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.